Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis

European Journal of Haematology

Volumn 97, Issue 4, 2016, Pages 321-330

  Doobaree, Indraraj Umesh ^a   Nandigam, Raghava ^a   Bennett, Dimitri ^b,c   Newland, Adrian ^a   Provan, Drew ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c Millennium: A Takeda Company   (United States)

Author keywords

immune thrombocytopenia; platelets; systematic review; thromboembolism

Indexed keywords

ADULT; ARTERIAL THROMBOEMBOLISM; BIBLIOGRAPHIC DATABASE; COHORT ANALYSIS; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; META ANALYSIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; SYSTEMATIC REVIEW; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 84986596466     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12777     Document Type: Review

References (52)

1. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168–86.
2. Semple JW, Provan D, Garvey MB, Freedman J. Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol 2010;17:590–5.
3. Nørgaard M, Jensen AØ, Engebjerg MC, Farkas DK, Thomsen RW, Cha S, Zhao S, Sørensen HT. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: A Danish population-based cohort study. Blood 2011;117:3514–20.
4. Feudjo-Tepie MA, Le Roux G, Beach KJ, Bennett D, Robinson NJ. Comorbidities of idiopathic thrombocytopenic purpura: a population-based study. Adv Hematol 2009; doi: 10.1155/2009/963506.
5. Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland AC, Sanderson S, Provan D. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010;95:1167–75.
6. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood 2009;114:2861–8.
7. Sewify EM, Sayed D, Abdel Aal RF, Ahmad HM, Abdou MA. Increased circulating red cell microparticles (RMP) and platelet microparticles (PMP) in immune thrombocytopenic purpura. Thromb Res 2013;131:e59–63.
8. Bidot L, Jy W, Bidot C Jr, Jimenez JJ, Fontana V, Horstman LL, Ahn YS. Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis. J Thromb Haemost 2008;6:913–9.
9. Davizon P, Lopez JA. Microparticles and thrombotic disease. Curr Opin Hematol 2009;16:334–41.
10. Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J. Metan: fixed- and random-effects meta-analysis. Stata Journal 2008;8:3–28.
11. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23:1351–75.
12. Gadenstatter M, Lamprecht B, Klingler A, Wetscher GJ, Greil R, Schmid T. Splenectomy versus medical treatment for idiopathic thrombocytopenic purpura. Am J Surg 2002;184:606–9; discussion 9-10.
13. Bennett D, Doobaree U, Nandigam R, Newland A, Provan D. Baseline characteristics, platelet count progression and occurrence of comorbidities among adult patients with primary immune thrombocytopenia (ITP): updated results from the UK ITP registry. Haematologica 2014;99:468.
14. Doobaree I, Nandigam R, Newland A, Provan A. Demographic characteristics, prevalent comorbidities and treatment patterns: initial analysis from the United Kingdom Immune Thrombocytopenia (UK ITP) Registry. Br J Haematol 2015;169:1–104.
15. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190–207.
16. Diagnosis treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. The American Society of Hematology ITP Practice Guideline Panel. Ann Intern Med 1997;126:319–26.
17. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3–40.
18. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386–93.
19. Enger C, Bennett D, Forssen U, Fogarty PF, McAfee AT. Comorbidities in patients with persistent or chronic immune thrombocytopenia. Int J Hematol 2010;92:289–95.
20. Schwartz J, Leber MD, Gillis S, Giunta A, Eldor A, Bussel JB. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 2003;72:94–8.
21. Kim KJ, Baek IW, Yoon CH, Kim WU, Cho CS. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol 2013;161:706–14.
22. Pierrot-Deseilligny Despujol C, Michel M, Khellaf M, Gouault M, Intrator L, Bierling P, Godeau B. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura. Br J Haematol 2008;142:638–43.
23. Kaya E, Erkurt MA, Aydogdu I, Kuku I, Ozhan O, Oner RI, Ulutas O. Retrospective analysis of patients with idiopathic thrombocytopenic purpura from Eastern Anatolia. Medical Princ Pract 2007;16:100–6.
24. Moulis G, Delavigne K, Huguet F, Fortenfant F, Beyne-Rauzy O, Adoue D. [Antiphospholipid antibodies and the risk of thrombosis: a comparative survey between chronic immune thrombocytopenia and primary antiphospholipid syndrome]. Rev Med Interne 2011;32:724–9.
25. Ruggeri M, Tosetto A, Palandri F, et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost 2014;12:1266–73.
26. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, Turgut M, Keskin H, Nalcaci M, Inanc M. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001;98:1760–4.
27. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003;122:966–74.
28. Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995;98:436–42.
29. Yang YJ, Yun GW, Song IC, et al. Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia. Korean J Intern Med 2011;26:449–54.
30. Vianelli N, Palandri F, Polverelli N, et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica 2013;98:875–80.
31. Qu Y, Xu J, Jiao C, Cheng Z, Ren S. Long-term outcomes of laparoscopic splenectomy versus open splenectomy for idiopathic thrombocytopenic purpura. Int Surg 2014;99:286–90.
32. Wang M, Zhang M, Zhou J, Wu Z, Zeng K, Peng B, Niu T. Predictive factors associated with long-term effects of laparoscopic splenectomy for chronic immune thrombocytopenia. Int J Hematol 2013;97:610–6.
33. Wang T, Xu M, Ji L, Han ZC, Yang R. Splenectomy for adult chronic idiopathic thrombocytopenic purpura: experience from a single center in China. Eur J Haematol 2005;75:424–9.
34. Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Derumeaux H, Adoue D. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity. Am J Hematol 2014;89:41–6.
35. Gonzalez-Porras JR, Escalante F, Pardal E, et al. Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. Eur J Haematol 2013;91:236–41.
36. Severinsen MT, Engebjerg MC, Farkas DK, Jensen AO, Norgaard M, Zhao S, Sorensen HT. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2011;152:360–2.
37. Nørgaard M, Severinsen MT, Lund Mægbæk M, Jensen AØ, Jensen S, Sørensen HT. Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2012;159:109–11.
38. Zoller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012;379:244–9.
39. Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood 2013;121:4782–90.
40. Bidot CJ, Jy W, Horstman LL, Ahn ER, Yaniz M, Ahn YS. Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS). Am J Hematol 2006;81:391–6.
41. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. Blood 2011;9:120–38.
42. George JN, Woolf SH, Raskob GE, et al. Blood 1996;88:3–40.
43. George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006;4:1664–72.
44. British Committee for Standards in Haematology General Haematology Task Force, Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults children and in pregnancy. Br J Haematol 2003;120:574–96.
45. Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, Keltai M, Diaz R, Rangarajan S, Yusuf S. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008;29:932–40.
46. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746–53.
47. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006;368:647–58.
48. Mohamed SY, Abdel-Nabi I, Inam A, Bakr M, El Tayeb K, Saleh AJ, Alzahrani H, Abdu SH. Systemic thromboembolic complications after laparoscopic splenectomy for idiopathic thrombocytopenic purpura in comparison to open surgery in the absence of anticoagulant prophylaxis. Hematol Oncol Stem Cell Ther 2010;3:71–7.
49. Svensson M, Wiren M, Kimby E, Hagglund H. Portal vein thrombosis is a common complication following splenectomy in patients with malignant haematological diseases. Eur J Haematol 2006;77:203–9.
50. Nichele I, Ruggeri M, Rodeghiero F. Venous thromboembolic events in primary immune thrombocytopenia (ITP) patients after splenectomy or during thrombopoietin receptor agonists (TPOra) therapy: single-centre experience. Haematologica 2013;98:44.
51. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004;76:205–13.
52. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Fontana V, Ahn YS. Transendothelial migration of leukocytes is promoted by plasma from a subgroup of immune thrombocytopenic purpura patients with small-vessel ischemic brain disease. Am J Hematol 2008;83:206–11.